1. Home
  2. REED vs NXL Comparison

REED vs NXL Comparison

Compare REED & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reed's Inc.

REED

Reed's Inc.

HOLD

Current Price

$1.05

Market Cap

9.1M

Sector

N/A

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.32

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
NXL
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.5M
IPO Year
2009
2022

Fundamental Metrics

Financial Performance
Metric
REED
NXL
Price
$1.05
$0.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.4K
133.3K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.76
EPS
N/A
N/A
Revenue
$34,065,000.00
$301,647.00
Revenue This Year
$18.74
$15.52
Revenue Next Year
$18.00
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
78.78
52 Week Low
$0.73
$0.31
52 Week High
$5.97
$2.00

Technical Indicators

Market Signals
Indicator
REED
NXL
Relative Strength Index (RSI) 52.80 38.80
Support Level $0.76 N/A
Resistance Level $1.42 $0.50
Average True Range (ATR) 0.11 0.02
MACD 0.04 -0.00
Stochastic Oscillator 69.59 15.47

Price Performance

Historical Comparison
REED
NXL

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Share on Social Networks: